insulin glulisine vs insulin NPH

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

insulin NPH · Humulin N

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glulisineinsulin NPH
HbA1c, change-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
—Not posted · NCT00604396
Body weight, change (kg)0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
12.6 vs 13vs Levemirn 42NCT01837680
HbA1c below 7%22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
—Not posted · NCT00604396
Fasting plasma glucose, change—Not posted · NCT00135057—Not posted · NCT00604396
3-point MACE (% with event)—Not posted · NCT00135057—Not posted · NCT00604396

HbA1c, change

insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
insulin NPH
—Not posted · NCT00604396

Body weight, change (kg)

insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
insulin NPH
12.6 vs 13vs Levemirn 42NCT01837680

HbA1c below 7%

insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
insulin NPH
—Not posted · NCT00604396

Fasting plasma glucose, change

insulin glulisine
—Not posted · NCT00135057
insulin NPH
—Not posted · NCT00604396

3-point MACE (% with event)

insulin glulisine
—Not posted · NCT00135057
insulin NPH
—Not posted · NCT00604396
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin glulisine: 4 of 4 rows · insulin NPH: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glulisineinsulin NPH
Dropout rate
23.5%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
19.2%a
NCT01837680 · Phase na · registry result, not featured evidence
Discontinued due to AEs
2.6%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—a
NCT01837680 · Phase na · registry result, not featured evidence
Serious AEs
11.9%Lantus/Apidra-1a
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%a
NCT01837680 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
a
biochemical event of hypoglycemia 26.9%
symptomatic hypoglycemia 21.2%
rash 11.5%
NCT01837680 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glulisine

HbA1c Less Than 7% 43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c -2.45% (n=144) vs -2.13% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-0.37% (n=49) vs -0.11% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
-0.48% (n=115) vs -0.46% (n=115) Insulin Lispro
NCT01194258 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 7% 51.1% (n=180) vs 39.5% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
22.4% (n=49) vs 8.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wk
absolute value · percentage points
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk
absolute change · mmol/L
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

insulin NPH

Glucose mg/dL 6.08 vs 5.96 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 109.5 mg/dL as posted
Glucose Target Attainment 66.7% (n=42) vs 77.8% (n=45) Levemir
event count · % of participants
NCT01837680 · Phase na · registry result, not featured evidence · converted to % from 28 Participants as posted
Time to Glycemic Control 1.15 vs 1.15 Levemir months
time to event · months
NCT01837680 · Phase na · registry result, not featured evidence · converted to months from 5 weeks as posted
Fasting Plasma Glucose mg/dL 5.59 vs 5.4 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 100.7 mg/dL as posted
Postprandial Plasma Glucose mg/dL 6.39 vs 6.27 Levemir mmol/L
absolute value · mmol/L
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 115.2 mg/dL as posted
Birth Weight Grams 3230 vs 3235 Levemir g
absolute value · g
NCT01837680 · Phase na · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · insulin NPH's landscape